Alzheimer’s disease (AD) currently afflicts more than 5 million Americans and healthcare costs for those who will be affected in 2050 are predicted to surpass one trillion dollars! It is a disease that takes away uniquely human traits and for which there is no cure. In addition, there appears to be little that we can do to delay or prevent its occurrence. However, a recent article published in Archives of Neurology may soon change that. Reductions in cerebral glucose metabolic rate (CMRglu) in the parieto-occipital, frontal and cingulate cortices are associated with increased AD risk and can be identified years before onset of dementia.
Physicians must choose among numerous treatment options for pain. Many pain syndromes would benefit from more effective approaches. Migraine headaches are a prime example of a painful condition in need of a better solution. Recent insights provided by research investigating the mechanisms causing migraines are beginning to generate new approaches to an old problem.